{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:00:12Z","timestamp":1787065212978,"version":"build-2736575974"},"reference-count":118,"publisher":"e-Century Publishing Corporation","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cancer Res"],"DOI":"10.62347\/dagz2151","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T06:12:04Z","timestamp":1767075124000},"page":"5140-5167","source":"Crossref","is-referenced-by-count":4,"title":["Pathogen spectrum and management strategies for opportunistic infections in lung cancer in the immunotherapy era: recent advances from fungi to mycobacteria"],"prefix":"10.62347","volume":"15","author":[{"given":"Wenlong","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I and Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74: 229-263.","journal-title":"CA Cancer J Clin"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"9394","DOI":"10.3390\/ijms22179394","article-title":"Links between infections, lung cancer, and the immune system","volume":"22","author":"Budisan","year":"2021","unstructured":"Budisan L, Zanoaga O, Braicu C, Pirlog R, Covaliu B, Esanu V, Korban SS and Berindan-Neagoe I. Links between infections, lung cancer, and the immune system. Int J Mol Sci 2021; 22: 9394.","journal-title":"Int J Mol Sci"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"5365","DOI":"10.62347\/BIBD8425","article-title":"Risk factors for postoperative pulmonary infections in non-small cell lung cancer: a regression-based nomogram prediction model","volume":"14","author":"Zhang","year":"2024","unstructured":"Zhang C, Fu Y, Chen Q and Liu R. Risk factors for postoperative pulmonary infections in non-small cell lung cancer: a regression-based nomogram prediction model. Am J Cancer Res 2024; 14: 5365-5377.","journal-title":"Am J Cancer Res"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.3390\/ijms24043110","article-title":"Bacterial infections and cancer: exploring this association and its implications for cancer patients","volume":"24","author":"Yusuf","year":"2023","unstructured":"Yusuf K, Sampath V and Umar S. Bacterial infections and cancer: exploring this association and its implications for cancer patients. Int Mol Sci 2023; 24: 3110.","journal-title":"Int Mol Sci"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(24)01756-2","article-title":"Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"JD","year":"2024","unstructured":"Spicer JD, Garassino MC, Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Arunachalam A, Keller SM, Samkari A and Gao S; KEYNOTE-671 Investigators. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2024; 404: 1240-1252.","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jtho.2021.11.001","article-title":"Lung cancer and severe acute respiratory syndrome coronavirus 2 infection: identifying important knowledge gaps for investigation","volume":"17","author":"Rolfo","year":"2022","unstructured":"Rolfo C, Meshulami N, Russo A, Krammer F, García-Sastre A, Mack PC, Gomez JE, Bhardwaj N, Benyounes A, Sirera R, Moore A, Rohs N, Henschke CI, Yankelevitz D, King J, Shyr Y, Bunn PA Jr, Minna JD and Hirsch FR. Lung cancer and severe acute respiratory syndrome coronavirus 2 infection: identifying important knowledge gaps for investigation. J Thorac Oncol 2022; 17: 214-227.","journal-title":"J Thorac Oncol"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Bavaro DF, Diella L, Pizzutilo P, Catino A, Signorile F, Pesola F, Belati A, Marech I, Garrisi V, Lamorgese N, Di Gennaro F, Saracino A and Galetta D. Incidence and predictors of infections in patients with advanced non-small cell lung cancer treated with checkpoint inhibitor immunotherapies: a monocentric retrospective cohort study. Scand J Immunol 2023; 98: e13303.","DOI":"10.1111\/sji.13303"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1159\/000541694","article-title":"Pulmonary nocardiosis in a non-small cell lung cancer patient being treated for pembrolizumab-associated pneumonitis","volume":"17","author":"Quartermain","year":"2024","unstructured":"Quartermain L, Buchan CA, Kilabuk E and Wheatley-Price P. Pulmonary nocardiosis in a non-small cell lung cancer patient being treated for pembrolizumab-associated pneumonitis. Case Rep Oncol 2024; 17: 1222-1228.","journal-title":"Case Rep Oncol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"10005","DOI":"10.21037\/apm-21-2364","article-title":"Analysis of the pathogenic bacteria, drug resistance, and risk factors of postoperative infection in patients with non-small cell lung cancer","volume":"10","author":"Chen","year":"2021","unstructured":"Chen Y, Wen F, Chen H, Zhao Y, Ding L, Lu W, Liu Y and Xue Y. Analysis of the pathogenic bacteria, drug resistance, and risk factors of postoperative infection in patients with non-small cell lung cancer. Ann Palliat Med 2021; 10: 10005-10012.","journal-title":"Ann Palliat Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"101365","DOI":"10.1016\/j.mycmed.2023.101365","article-title":"Detection of Pneumocystis jirovecii by PCR in patients with lung cancer: a preliminary study","volume":"33","author":"Bagci","year":"2023","unstructured":"Bagci OU, Guldaval F, Muftuoglu C, Mert U, Toz S, Unat DS, Unat OS, Polat G and Caner A. Detection of Pneumocystis jirovecii by PCR in patients with lung cancer: a preliminary study. J Mycol Med 2023; 33: 101365.","journal-title":"J Mycol Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1398357","DOI":"10.3389\/fonc.2024.1398357","article-title":"Immune checkpoint inhibitor increased mortality in lung cancer patients with Pneumocystis jirovecii pneumonia: a comparative retrospective cohort study","volume":"14","author":"Fan","year":"2024","unstructured":"Fan B, Sun X, Han W, Zou Y, Chen F, Lan F, Li W and Mao Y. Immune checkpoint inhibitor increased mortality in lung cancer patients with Pneumocystis jirovecii pneumonia: a comparative retrospective cohort study. Front Oncol 2024; 14: 1398357.","journal-title":"Front Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.3855\/jidc.15840","article-title":"Pneumocystis jirovecii colonization in bronchoalveolar lavage among naïve non-small cell lung cancer from tertiary respiratory hospital in Jakarta, Indonesia","volume":"16","author":"Zaini","year":"2022","unstructured":"Zaini J, A’La Al Maududi A, Fillahihasanah T, Rizqy Fadhillah M, Pradono P, Haryanto B, Adawiyah R, Setianingrum F, Rozaliyani A and Syahruddin E. Pneumocystis jirovecii colonization in bronchoalveolar lavage among naïve non-small cell lung cancer from tertiary respiratory hospital in Jakarta, Indonesia. J Infect Dev Ctries 2022; 16: 1643-1647.","journal-title":"J Infect Dev Ctries"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"101728","DOI":"10.1016\/j.smim.2023.101728","article-title":"Immunity to fungi in the lung","volume":"66","author":"Heung","year":"2023","unstructured":"Heung LJ, Wiesner DL, Wang K, Rivera A and Hohl TM. Immunity to fungi in the lung. Semin Immunol 2023; 66: 101728.","journal-title":"Semin Immunol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/07357907.2022.2153860","article-title":"The Spectrum of infections in patients with lung cancer","volume":"41","author":"Serce Unat","year":"2023","unstructured":"Serce Unat D, Ulusan Bagci O, Unat OS, Kose S and Caner A. The Spectrum of infections in patients with lung cancer. Cancer Invest 2023; 41: 25-42.","journal-title":"Cancer Invest"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1007\/s12672-025-02627-8","article-title":"Pneumocystis jirovecii pneumonia in patients with lung cancer receiving immune checkpoint inhibitors: a retrospective nationwide population-based cohort study from South Korea","volume":"16","author":"Jung","year":"2025","unstructured":"Jung J, Park SY, Jo HB, Park JY, Kim D, Lee K and Choi S. Pneumocystis jirovecii pneumonia in patients with lung cancer receiving immune checkpoint inhibitors: a retrospective nationwide population-based cohort study from South Korea. Discov Oncol 2025; 16: 950.","journal-title":"Discov Oncol"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Denning DW. Global incidence and mortality of severe fungal disease. Lancet Infect Dis 2024; 24: e428-e438.","DOI":"10.1016\/S1473-3099(23)00692-8"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S2213-2600(22)00259-4","article-title":"Lung epithelial and myeloid innate immunity in influenza-associated or COVID-19-associated pulmonary aspergillosis: an observational study","volume":"10","author":"Feys","year":"2022","unstructured":"Feys S, Gonçalves SM, Khan M, Choi S, Boeckx B, Chatelain D, Cunha C, Debaveye Y, Hermans G, Hertoghs M, Humblet-Baron S, Jacobs C, Lagrou K, Marcelis L, Maizel J, Meersseman P, Nyga R, Seldeslachts L, Starick MR, Thevissen K, Vandenbriele C, Vanderbeke L, Vande Velde G, Van Regenmortel N, Vanstapel A, Vanmassenhove S, Wilmer A, Van De Veerdonk FL, De Hertogh G, Mombaerts P, Lambrechts D, Carvalho A, Van Weyenbergh J and Wauters J. Lung epithelial and myeloid innate immunity in influenza-associated or COVID-19-associated pulmonary aspergillosis: an observational study. Lancet Respir Med 2022; 10: 1147-1159.","journal-title":"Lancet Respir Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"101385","DOI":"10.1016\/j.mycmed.2023.101385","article-title":"Instillation of Amphotericin B by bronchoscopy combined with systemic voriconazole in advanced non-small cell lung cancer patients with chronic cavitary pulmonary aspergillosis: a case series and literature review","volume":"33","author":"Wu","year":"2023","unstructured":"Wu H, Xiong X, Han Q, Zhuo K, Wang K and Cheng D. Instillation of Amphotericin B by bronchoscopy combined with systemic voriconazole in advanced non-small cell lung cancer patients with chronic cavitary pulmonary aspergillosis: a case series and literature review. J Mycol Med 2023; 33: 101385.","journal-title":"J Mycol Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"105133","DOI":"10.12998\/wjcc.v13.i20.105133","article-title":"Invasive pulmonary cryptococcosis mimicking metastatic lung cancer: a case report and review of literature","volume":"13","author":"Gao","year":"2025","unstructured":"Gao CY, Yang XJ, Guo E and Zheng YL. Invasive pulmonary cryptococcosis mimicking metastatic lung cancer: a case report and review of literature. World J Clin Cases 2025; 13: 105133.","journal-title":"World J Clin Cases"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.2169\/internalmedicine.6811-20","article-title":"Safe concurrent use of anti-tuberculosis drugs and pembrolizumab in a patient with non-small-cell lung cancer who was infected with Mycobacterium tuberculosis","volume":"61","author":"Nakahama","year":"2022","unstructured":"Nakahama K, Kaneda H, Ogawa K, Matsumoto Y, Tani Y, Suzumura T, Mitsuoka S, Watanabe T, Asai K and Kawaguchi T. Safe concurrent use of anti-tuberculosis drugs and pembrolizumab in a patient with non-small-cell lung cancer who was infected with Mycobacterium tuberculosis. Intern Med 2022; 61: 1039-1042.","journal-title":"Intern Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"10732748251320822","DOI":"10.1177\/10732748251320822","article-title":"The association between tumor burden and the efficacy of immunotherapy among patients with non-small cell lung cancer","volume":"32","author":"Hui","year":"2025","unstructured":"Hui JJ, Yan HL, Ding SJ, Qin BD, Jiao XD and Zang YS. The association between tumor burden and the efficacy of immunotherapy among patients with non-small cell lung cancer. Cancer Control 2025; 32: 10732748251320822.","journal-title":"Cancer Control"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.3390\/ijerph20021282","article-title":"The bidirectional relationship between pulmonary tuberculosis and lung cancer","volume":"20","author":"Preda","year":"2023","unstructured":"Preda M, Tănase BC, Zob DL, Gheorghe AS, Lungulescu CV, Dumitrescu EA, Stănculeanu DL, Manolescu LSC, Popescu O, Ibraim E and Mahler B. The bidirectional relationship between pulmonary tuberculosis and lung cancer. Int J Environ Res Public Health 2023; 20: 1282.","journal-title":"Int J Environ Res Public Health"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.21037\/tlcr-21-465","article-title":"Advances in molecular mechanisms of interaction between Mycobacterium tuberculosis and lung cancer: a narrative review","volume":"10","author":"Xiong","year":"2021","unstructured":"Xiong K, Sun W, He Y and Fan L. Advances in molecular mechanisms of interaction between Mycobacterium tuberculosis and lung cancer: a narrative review. Transl Lung Cancer Res 2021; 10: 4012-4026.","journal-title":"Transl Lung Cancer Res"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"8332","DOI":"10.3390\/ijms22158332","article-title":"Dual nature of relationship between mycobacteria and cancer","volume":"22","author":"Fol","year":"2021","unstructured":"Fol M, Koziński P, Kulesza J, Białecki P and Druszczyńska M. Dual nature of relationship between mycobacteria and cancer. Int J Mol Sci 2021; 22: 8332.","journal-title":"Int J Mol Sci"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.3390\/microorganisms9122460","article-title":"T-cell exhaustion in Mycobacterium tuberculosis and nontuberculous mycobacteria Infection: pathophysiology and therapeutic perspectives","volume":"9","author":"Lombardi","year":"2021","unstructured":"Lombardi A, Villa S, Castelli V, Bandera A and Gori A. T-cell exhaustion in Mycobacterium tuberculosis and nontuberculous mycobacteria Infection: pathophysiology and therapeutic perspectives. Microorganisms 2021; 9: 2460.","journal-title":"Microorganisms"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"909274","DOI":"10.3389\/fmicb.2022.909274","article-title":"The Impact of nontuberculous mycobacteria species on mortality in patients with nontuberculous mycobacterial lung disease","volume":"13","author":"Wang","year":"2022","unstructured":"Wang PH, Pan SW, Wang SM, Shu CC and Chang CH. The Impact of nontuberculous mycobacteria species on mortality in patients with nontuberculous mycobacterial lung disease. Front Microbiol 2022; 13: 909274.","journal-title":"Front Microbiol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.3390\/diagnostics12051086","article-title":"Risk factors for the development of nontuberculous mycobacteria pulmonary disease during long-term follow-up after lung cancer surgery","volume":"12","author":"Kim","year":"2022","unstructured":"Kim BG, Choi YS, Shin SH, Lee K, Um SW, Kim H, Cho JH, Kim HK, Kim J, Shim YM and Jeong BH. Risk factors for the development of nontuberculous mycobacteria pulmonary disease during long-term follow-up after lung cancer surgery. Diagnostics (Basel) 2022; 12: 1086.","journal-title":"Diagnostics (Basel)"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"5619","DOI":"10.3390\/jcm11195619","article-title":"Non-tuberculous mycobacteria and Aspergillus lung co-infection: systematic review","volume":"11","author":"Fayos","year":"2022","unstructured":"Fayos M, Silva JT, López-Medrano F and Aguado JM. Non-tuberculous mycobacteria and Aspergillus lung co-infection: systematic review. J Clin Med 2022; 11: 5619.","journal-title":"J Clin Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"577514","DOI":"10.3389\/fonc.2021.577514","article-title":"Viral infection and lung cancer immunotherapy","volume":"11","author":"Kalinka","year":"2021","unstructured":"Kalinka E, Chmielewska I and Wojas-Krawczyk K. Viral infection and lung cancer immunotherapy. Front Oncol 2021; 11: 577514.","journal-title":"Front Oncol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.cmi.2021.01.016","article-title":"Cutaneous cytomegalovirus (CMV) infection in a patient with metastasized lung cancer","volume":"27","author":"Lee","year":"2021","unstructured":"Lee CN, Po-Chao Chiu F and Hsu CK. Cutaneous cytomegalovirus (CMV) infection in a patient with metastasized lung cancer. Clin Microbiol Infect 2021; 27: 565-567.","journal-title":"Clin Microbiol Infect"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s12262-020-02339-z","article-title":"Relationship among three different viruses and primary lung cancer","volume":"83","author":"Shen","year":"2021","unstructured":"Shen C, Ren J and Che G. Relationship among three different viruses and primary lung cancer. Indian Journal of Surgery 2021; 83: 230-236.","journal-title":"Indian Journal of Surgery"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/irv.12643","article-title":"Epidemiology and outcomes of hospitalized adults with respiratory syncytial virus: a 6-year retrospective study","volume":"13","author":"Schmidt","year":"2019","unstructured":"Schmidt H, Das A, Nam H, Yang A and Ison MG. Epidemiology and outcomes of hospitalized adults with respiratory syncytial virus: a 6-year retrospective study. Influenza Other Respir Viruses 2019; 13: 331-338.","journal-title":"Influenza Other Respir Viruses"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.3724\/abbs.2022147","article-title":"Health influence of SARS-CoV-2 (COVID-19) on cancer: a review","volume":"54","author":"Parise","year":"2022","unstructured":"Parise R, Li YE, Nadar RM, Ramesh S, Ren J, Govindarajulu MY, Moore T and Dhanasekaran M. Health influence of SARS-CoV-2 (COVID-19) on cancer: a review. Acta Biochim Biophys Sin (Shanghai) 2022; 54: 1395-1405.","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.3390\/cancers17091536","article-title":"SARS-CoV-2 infection risk and COVID-19 prevalence and mortality in cancer patients during the first wave of COVID-19 pandemic in a virus epicenter in Northern Italy","volume":"17","author":"Corian&#xF2","year":"2025","unstructured":"Corianò M, Isella L, Tommasi C, Pellegrino B, Michiara M, Boggiani D, Pucci F, Leonetti A, Bizzoco S, Affanni P, Veronesi L, Rapacchi E, Serra O, Sgargi P, Maglietta G and Musolino A. SARS-CoV-2 infection risk and COVID-19 prevalence and mortality in cancer patients during the first wave of COVID-19 pandemic in a virus epicenter in Northern Italy. Cancers (Basel) 2025; 17: 1536.","journal-title":"Cancers (Basel)"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1257638","DOI":"10.3389\/fcimb.2023.1257638","article-title":"The impact of concurrent bacterial lung infection on immunotherapy in patients with non-small cell lung cancer: a retrospective cohort study","volume":"13","author":"Cao","year":"2023","unstructured":"Cao Q, Wu X, Chen Y, Wei Q, You Y, Qiang Y and Cao G. The impact of concurrent bacterial lung infection on immunotherapy in patients with non-small cell lung cancer: a retrospective cohort study. Front Cell Infect Microbiol 2023; 13: 1257638.","journal-title":"Front Cell Infect Microbiol"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Xu B, Wang X, Li X, Khan MN, Shafiq M, Khan S, Yu T, Khan RU, Song Y, Qiu H, Lv QL and Bilal H. Six-year retrospective analysis of the epidemiology and risk factors of multidrug-resistant bloodstream infections in oncology patients in Jiangxi, China. Microbiol Spectr 2025; e0146825.","DOI":"10.1128\/spectrum.01468-25"},{"key":"ref36","unstructured":"Chen RX, Liu XN, Xu Y, Shi YJ, Wang MQ, Shao C, Huang H, Xu K, Wang MZ and Xu ZJ. Clinical features and prognostic analysis of checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer. Zhonghua Jie He He Hu Xi Za Zhi 2024; 47: 207-213."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3390\/pathogens10020237","article-title":"Pneumocystis jirovecii pneumonia prophylaxis for cancer patients during chemotherapy","volume":"10","author":"Takeuchi","year":"2021","unstructured":"Takeuchi K and Yakushijin Y. Pneumocystis jirovecii pneumonia prophylaxis for cancer patients during chemotherapy. Pathogens 2021; 10: 237.","journal-title":"Pathogens"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1186\/s12885-025-13743-7","article-title":"Incidence and risk factors of serious infections occurred in patients with lung cancer following immune checkpoint blockade therapy","volume":"25","author":"Wang","year":"2025","unstructured":"Wang X, Wu YX, Hu WP and Zhang J. Incidence and risk factors of serious infections occurred in patients with lung cancer following immune checkpoint blockade therapy. BMC Cancer 2025; 25: 307.","journal-title":"BMC Cancer"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Chen HW, Kuo YW, Chen CY, Chang CH, Wang SM, Chien YC, Lu WC, Chen JP, Chang CY, Wei YF, Chang SC, Shu CC, Wang JY, Liao WY, Wang HC and Yu CJ. Increased tuberculosis reactivation risk in patients receiving immune checkpoint inhibitor-based therapy. Oncologist 2024; 29: e498-e506.","DOI":"10.1093\/oncolo\/oyad340"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/S0140-6736(24)00367-2","article-title":"Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"403","author":"2021 Causes of Death Collaborators","year":"2024","unstructured":"GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 2024; 403: 2100-2132.","journal-title":"Lancet"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1560288","DOI":"10.3389\/fmed.2025.1560288","article-title":"Incidence and predictors of pulmonary aspergillosis in patients with lung cancer: a systematic review and meta-analysis","volume":"12","author":"Teng","year":"2025","unstructured":"Teng G, Jin F, Zhang H and Zhang M. Incidence and predictors of pulmonary aspergillosis in patients with lung cancer: a systematic review and meta-analysis. Front Med (Lausanne) 2025; 12: 1560288.","journal-title":"Front Med (Lausanne)"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S1470-2045(03)01218-X","article-title":"Infections in patients with cancer undergoing chemotherapy: aetiology, prevention, and treatment","volume":"4","author":"Vento","year":"2003","unstructured":"Vento S and Cainelli F. Infections in patients with cancer undergoing chemotherapy: aetiology, prevention, and treatment. Lancet Oncol 2003; 4: 595-604.","journal-title":"Lancet Oncol"},{"key":"ref43","unstructured":"Wingard J. Risk assessment of adults with chemotherapy-induced neutropenia. UpToDate 2022; 2: 0-1."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S2213-2600(24)00264-9","article-title":"Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study","volume":"13","author":"L&#xE9","year":"2025","unstructured":"Léna H, Greillier L, Cropet C, Bylicki O, Monnet I, Audigier-Valette C, Falchero L, Vergnenègre A, Demontrond P, Geier M, Guisier F, Hominal S, Locher C, Corre R, Chouaid C and Ricordel C; GFPC 08-2015 ENERGY investigators. Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study. Lancet Respir Med 2025; 13: 141-152.","journal-title":"Lancet Respir Med"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.21873\/anticanres.16280","article-title":"Bevacizumab plus carboplatin plus nab-paclitaxel for non-squamous non-small cell lung cancer in a real-world setting","volume":"43","author":"Tamiya","year":"2023","unstructured":"Tamiya A, Tamiya M, Inagaki Y, Taniguchi Y, Nakao K, Matsuda Y, Kawamura T, Kunimasa K, Inoue T, Nishino K and Okishio K. Bevacizumab plus carboplatin plus nab-paclitaxel for non-squamous non-small cell lung cancer in a real-world setting. Anticancer Res 2023; 43: 1325-1330.","journal-title":"Anticancer Res"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1186\/s12885-025-14896-1","article-title":"Effectiveness and safety of pirfenidone for radiation-induced lung injury in non-small cell lung cancer: a retrospective pilot study","volume":"25","author":"Liu","year":"2025","unstructured":"Liu X, Lu F, Yang H, Liao G, Zhao L, Zou D, He T, Hu Y, Wang L, Xia J, Li B, Huang Z, Wang M, Lu B, Su S and Peng J. Effectiveness and safety of pirfenidone for radiation-induced lung injury in non-small cell lung cancer: a retrospective pilot study. BMC Cancer 2025; 25: 1415.","journal-title":"BMC Cancer"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.athoracsur.2020.07.068","article-title":"Chronic lung injury after trimodality therapy for locally advanced non-small cell lung cancer","volume":"112","author":"Soh","year":"2021","unstructured":"Soh J, Sugimoto S, Namba K, Miura A, Shiotani T, Yamamoto H, Suzawa K, Shien K, Yamamoto H, Okazaki M, Katsui K, Yamane M, Kiura K, Kanazawa S and Toyooka S. Chronic lung injury after trimodality therapy for locally advanced non-small cell lung cancer. Ann Thorac Surg 2021; 112: 279-288.","journal-title":"Ann Thorac Surg"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.clon.2021.06.010","article-title":"Reducing the risk of death from Pneumocystis jirovecii pneumonia after radical radiation therapy to the lung","volume":"33","author":"McAleese","year":"2021","unstructured":"McAleese J, Mooney L and Walls GM. Reducing the risk of death from Pneumocystis jirovecii pneumonia after radical radiation therapy to the lung. Clin Oncol (R Coll Radiol) 2021; 33: 780-787.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1758835920922033","DOI":"10.1177\/1758835920922033","article-title":"Association of immune-related pneumonitis with the efficacy of PD-1\/PD-L1 inhibitors in non-small cell lung cancer","volume":"12","author":"Cui","year":"2020","unstructured":"Cui P, Huang D, Wu Z, Tao H, Zhang S, Ma J, Liu Z, Wang J, Huang Z, Chen S, Zheng X and Hu Y. Association of immune-related pneumonitis with the efficacy of PD-1\/PD-L1 inhibitors in non-small cell lung cancer. Ther Adv Med Oncol 2020; 12: 1758835920922033.","journal-title":"Ther Adv Med Oncol"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Shah NJ, Cook MR, Wu T, Lev-Ari S, Blackburn MJ, Serzan MT, Alaoui A, Ahn J and Atkins MB. The risk of opportunistic infections and the role of antibiotic prophylaxis in patients on checkpoint inhibitors requiring steroids. J Natl Compr Canc Netw 2022; 20: 800-807, e1.","DOI":"10.6004\/jnccn.2022.7020"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s10147-025-02696-3","article-title":"Five-year outcomes with gefitinib induction and chemoradiotherapy in EGFR-mutant stage III non-small-cell lung cancer: LOGIK0902\/OLCSG0905 phase II study","volume":"30","author":"Hotta","year":"2025","unstructured":"Hotta K, Saeki S, Sakata S, Yamaguchi M, Harada D, Bessho A, Tanaka K, Inoue K, Inoue K, Gemba K, Kubo T, Sato A, Ichihara E, Watanabe H, Kishimoto J, Shioyama Y, Katsui K, Sugio K and Kiura K. Five-year outcomes with gefitinib induction and chemoradiotherapy in EGFR-mutant stage III non-small-cell lung cancer: LOGIK0902\/OLCSG0905 phase II study. Int J Clin Oncol 2025; 30: 497-503.","journal-title":"Int J Clin Oncol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s11523-024-01116-2","article-title":"Immunotherapy following anaplastic lymphoma kinase inhibitor therapy for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in Japan","volume":"20","author":"Shimomura","year":"2025","unstructured":"Shimomura Y, Mizutani M, Yoshida H, Ihara Y and Shintani A. Immunotherapy following anaplastic lymphoma kinase inhibitor therapy for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in Japan. Target Oncol 2025; 20: 171-180.","journal-title":"Target Oncol"},{"key":"ref53","unstructured":"Tran D. Impact of concurrent antibiotic & corticosteroid use on efficacy of immune checkpoint inhibitors. University of Minnesota 2023; 30245762."},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Kubeček O, Paterová P and Novosadová M. Risk factors for infections, antibiotic therapy, and its impact on cancer therapy outcomes for patients with solid tumors. Life (Basel) 2021; 11: 1387.","DOI":"10.3390\/life11121387"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/ptr.6790","article-title":"Clinical efficacy and safety of Tanreqing injection combined with antibiotics versus antibiotics alone in the treatment of pulmonary infection patients after chemotherapy with lung cancer: a systematic review and meta-analysis","volume":"35","author":"Tong","year":"2021","unstructured":"Tong Y, Wen J, Yang T, Li H, Wei S, Jing M, Wang M, Zou W and Zhao Y. Clinical efficacy and safety of Tanreqing injection combined with antibiotics versus antibiotics alone in the treatment of pulmonary infection patients after chemotherapy with lung cancer: a systematic review and meta-analysis. Phytother Res 2021; 35: 122-137.","journal-title":"Phytother Res"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"107290","DOI":"10.1016\/j.ijid.2024.107290","article-title":"Preventing central line-associated bloodstream infections: a position paper of the International Society for Infectious Diseases, 2024 update","volume":"150","author":"Rosenthal","year":"2025","unstructured":"Rosenthal VD, Memish ZA, Shweta F, Bearman G and Lutwick LI. Preventing central line-associated bloodstream infections: a position paper of the International Society for Infectious Diseases, 2024 update. Int J Infect Dis 2025; 150: 107290.","journal-title":"Int J Infect Dis"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.ajic.2023.12.010","article-title":"Decreasing central line-associated bloodstream infections rates in intensive care units in 30 low- and middle-income countries: An INICC approach","volume":"52","author":"Rosenthal","year":"2024","unstructured":"Rosenthal VD, Jin Z, Brown EC, Dongol R, De Moros DA, Alarcon-Rua J, Perez V, Stagnaro JP, Alkhawaja S, Jimenez-Alvarez LF, Cano-Medina YA, Valderrama-Beltran SL, Henao-Rodas CM, Zuniga-Chavarria MA, El-Kholy A, Agha H, Sahu S, Mishra SB, Bhattacharyya M, Kharbanda M, Poojary A, Nair PK, Myatra SN, Chawla R, Sandhu K, Mehta Y, Rajhans P, Abdellatif-Daboor M, Chian-Wern T, Gan CS, Mohd-Basri MN, Aguirre-Avalos G, Hernandez-Chena BE, Sassoe-Gonzalez A, Villegas-Mota I, Aleman-Bocanegra MC, Bat-Erdene I, Carreazo NY, Castaneda-Sabogal A, Janc J, Hlinkova S, Yildizdas D, Havan M, Koker A, Sungurtekin H, Dinleyici EC, Guclu E, Tao L, Memish ZA and Yin R. Decreasing central line-associated bloodstream infections rates in intensive care units in 30 low- and middle-income countries: An INICC approach. Am J Infect Control 2024; 52: 580-587.","journal-title":"Am J Infect Control"},{"key":"ref58","unstructured":"Hazer S, Gülhan SŞ E, Solak N, Yenibertiz D, Akıllı MS, Sayilir Guven E and Bıçakçıoğlu P. The effect of prognostic nutritional index in postoperative infection following lobectomy in non-small cell lung cancer patients. Cureus 2023; 15: e37611."},{"key":"ref59","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/jebm.12544","article-title":"Surgical site infection following open lobectomy in patients with lung cancer: a prospective study","volume":"16","author":"Li","year":"2023","unstructured":"Li S, Lin J, Ye L, Qiao F, Huang W, Peng Y and Huang J. Surgical site infection following open lobectomy in patients with lung cancer: a prospective study. J Evid Based Med 2023; 16: 194-199.","journal-title":"J Evid Based Med"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"757","DOI":"10.3390\/biology11050757","article-title":"Cancer-associated microbiota: from mechanisms of disease causation to microbiota-centric anti-cancer approaches","volume":"11","author":"Dey","year":"2022","unstructured":"Dey P and Ray Chaudhuri S. Cancer-associated microbiota: from mechanisms of disease causation to microbiota-centric anti-cancer approaches. Biology (Basel) 2022; 11: 757.","journal-title":"Biology (Basel)"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1055\/a-1482-8336","article-title":"Radiological CT patterns and distribution of invasive pulmonary aspergillus, non-aspergillus, cryptococcus and pneumocystis jirovecii mold infections - a multicenter study","volume":"193","author":"Obmann","year":"2021","unstructured":"Obmann VC, Bickel F, Hosek N, Ebner L, Huber AT, Damonti L, Zimmerli S and Christe A. Radiological CT patterns and distribution of invasive pulmonary aspergillus, non-aspergillus, cryptococcus and pneumocystis jirovecii mold infections - a multicenter study. Rofo 2021; 193: 1304-1314.","journal-title":"Rofo"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"6089","DOI":"10.1007\/s00330-019-06235-3","article-title":"Differential diagnosis of pulmonary infections in immunocompromised patients using high-resolution computed tomography","volume":"29","author":"Kunihiro","year":"2019","unstructured":"Kunihiro Y, Tanaka N, Kawano R, Yujiri T, Kubo M, Ueda K, Gondo T, Kobayashi T and Matsumoto T. Differential diagnosis of pulmonary infections in immunocompromised patients using high-resolution computed tomography. Eur Radiol 2019; 29: 6089-6099.","journal-title":"Eur Radiol"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12890-021-01512-8","article-title":"Dynamic monitor of CT scan within short interval in invasive pulmonary aspergillosis for nonneutropenic patients: a retrospective analysis in two centers","volume":"21","author":"Chen","year":"2021","unstructured":"Chen F, Zhong Y, Li N, Wang H, Tan Y, Zhang H, Hua W, Mao Y and Huang H. Dynamic monitor of CT scan within short interval in invasive pulmonary aspergillosis for nonneutropenic patients: a retrospective analysis in two centers. BMC Pulm Med 2021; 21: 142.","journal-title":"BMC Pulm Med"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Sun W, Zhang L, Liang J, Li X, Yang Y, Sun W and Hou J. Comparison of clinical and imaging features between pulmonary tuberculosis complicated with lung cancer and simple pulmonary tuberculosis: a systematic review and meta-analysis. Epidemiol Infect 2022; 150: e43.","DOI":"10.1017\/S0950268822000176"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1186\/s12879-021-06614-6","article-title":"Machine learning-based CT radiomics model distinguishes COVID-19 from non-COVID-19 pneumonia","volume":"21","author":"Chen","year":"2021","unstructured":"Chen HJ, Mao L, Chen Y, Yuan L, Wang F, Li X, Cai Q, Qiu J and Chen F. Machine learning-based CT radiomics model distinguishes COVID-19 from non-COVID-19 pneumonia. BMC Infect Dis 2021; 21: 931.","journal-title":"BMC Infect Dis"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/MNM.0000000000001667","article-title":"Machine learning approach using 18 F-FDG PET-based radiomics in differentiation of lung adenocarcinoma with bronchoalveolar distribution and infection","volume":"44","author":"Ag&#xFC","year":"2023","unstructured":"Agüloğlu N, Aksu A and Unat DS. Machine learning approach using 18 F-FDG PET-based radiomics in differentiation of lung adenocarcinoma with bronchoalveolar distribution and infection. Nucl Med Commun 2023; 44: 302-308.","journal-title":"Nucl Med Commun"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/s13054-023-04608-1","article-title":"Pneumocystis jirovecii pneumonia in intensive care units: a multicenter study by ESGCIP and EFISG","volume":"27","author":"DR","year":"2023","unstructured":"Giacobbe DR, Dettori S, Di Pilato V, Asperges E, Ball L, Berti E, Blennow O, Bruzzone B, Calvet L, Capra Marzani F, Casabella A, Choudaly S, Dartevel A, De Pascale G, Di Meco G, Fallon M, Galerneau LM, Gallego M, Giacomini M, González Sáez A, Hänsel L, Icardi G, Koehler P, Lagrou K, Lahmer T, Lewis White P, Magnasco L, Marchese A, Marelli C, Marín-Arriaza M, Martin-Loeches I, Mekontso-Dessap A, Mikulska M, Mularoni A, Nordlander A, Poissy J, Russelli G, Signori A, Tascini C, Vaconsin LM, Vargas J, Vena A, Wauters J, Pelosi P, Timsit JF and Bassetti M; JIR-ICU investigators (collaborators); Critically Ill Patients Study Group of the European Society of Clinical Microbiology and Infectious Diseases (ESGCIP), and the Fungal Infection Study Group of the European Society of Clinical Microbiology and Infectious Diseases (EFISG). Pneumocystis jirovecii pneumonia in intensive care units: a multicenter study by ESGCIP and EFISG. Crit Care 2023; 27: 323.","journal-title":"Crit Care"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12931-025-03127-7","article-title":"One-step diagnosis of infection and lung cancer using metagenomic sequencing","volume":"26","author":"Li","year":"2025","unstructured":"Li S, Zhan Y, Wang Y, Li W, Wang X, Wang H, Sun W, Cao X, Li Z and Ye F. One-step diagnosis of infection and lung cancer using metagenomic sequencing. Respir Res 2025; 26: 48.","journal-title":"Respir Res"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"20251180","DOI":"10.1515\/med-2025-1180","article-title":"Pathogen surveillance and risk factors for pulmonary infection in patients with lung cancer: a retrospective single-center study","volume":"20","author":"Shan","year":"2025","unstructured":"Shan H, Wang J, Zhang Q, Ming Z, Zhang Y, He P, Fang P, Zhang M, Li W, Shi H, Guan Y and Yang S. Pathogen surveillance and risk factors for pulmonary infection in patients with lung cancer: a retrospective single-center study. Open Med (Wars) 2025; 20: 20251180.","journal-title":"Open Med (Wars)"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"112","DOI":"10.21037\/jtd-22-1732","article-title":"A multicenter-retrospective cohort study of chromosome instability in lung cancer: clinical characteristics and prognosis of patients harboring chromosomal instability detected by metagenomic next-generation sequencing","volume":"15","author":"Lin","year":"2023","unstructured":"Lin P, Chen Y, Xu J, Huang X, Wen W, Zhang L, Kong W, Zhao Z, Ye Y, Bao Z, Song Y, Lin S and Yu Z. A multicenter-retrospective cohort study of chromosome instability in lung cancer: clinical characteristics and prognosis of patients harboring chromosomal instability detected by metagenomic next-generation sequencing. J Thorac Dis 2023; 15: 112-122.","journal-title":"J Thorac Dis"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12890-022-01894-3","article-title":"Diagnosis of lung squamous cell carcinoma based on metagenomic Next-Generation Sequencing","volume":"22","author":"Wei","year":"2022","unstructured":"Wei P, Gao Y, Zhang J, Lin J, Liu H, Chen K, Lin W, Wang X, Wang C and Liu C. Diagnosis of lung squamous cell carcinoma based on metagenomic Next-Generation Sequencing. BMC Pulm Med 2022; 22: 108.","journal-title":"BMC Pulm Med"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"15683","DOI":"10.1038\/s41598-025-98424-y","article-title":"Characterizations of lung cancer microbiome and exploration of potential microbial risk factors for lung cancer","volume":"15","author":"Yiminniyaze","year":"2025","unstructured":"Yiminniyaze R, Zhang Y, Zhu N, Zhang X, Wang J, Li C, Wumaier G, Zhou D, Xia J, Li S, Dong L, Zhang Y, Zhang Y and Li S. Characterizations of lung cancer microbiome and exploration of potential microbial risk factors for lung cancer. Sci Rep 2025; 15: 15683.","journal-title":"Sci Rep"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-Programmed Death-1\/Programmed Death Ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","unstructured":"Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, Chaft JE, Segal NH, Callahan MK, Lesokhin AM, Rosenberg J, Voss MH, Rudin CM, Rizvi H, Hou X, Rodriguez K, Albano M, Gordon RA, Leduc C, Rekhtman N, Harris B, Menzies AM, Guminski AD, Carlino MS, Kong BY, Wolchok JD, Postow MA, Long GV and Hellmann MD. Pneumonitis in patients treated with anti-Programmed Death-1\/Programmed Death Ligand 1 therapy. J Clin Oncol 2017; 35: 709-717.","journal-title":"J Clin Oncol"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"JC","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y and Ramalingam SS; FLAURA Investigators. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 2018; 378: 113-125.","journal-title":"N Engl J Med"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1148\/radiol.2021203427","article-title":"Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: a position paper from the fleischner society","volume":"298","author":"Johkoh","year":"2021","unstructured":"Johkoh T, Lee KS, Nishino M, Travis WD, Ryu JH, Lee HY, Ryerson CJ, Franquet T, Bankier AA, Brown KK, Goo JM, Kauczor HU, Lynch DA, Nicholson AG, Richeldi L, Schaefer-Prokop CM, Verschakelen J, Raoof S, Rubin GD, Powell C, Inoue Y and Hatabu H. Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: a position paper from the fleischner society. Radiology 2021; 298: 550-566.","journal-title":"Radiology"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"870842","DOI":"10.3389\/fimmu.2022.870842","article-title":"Development and validation of a radiomics nomogram using computed tomography for differentiating immune checkpoint inhibitor-related pneumonitis from radiation pneumonitis for patients with non-small cell lung cancer","volume":"13","author":"Qiu","year":"2022","unstructured":"Qiu Q, Xing L, Wang Y, Feng A and Wen Q. Development and validation of a radiomics nomogram using computed tomography for differentiating immune checkpoint inhibitor-related pneumonitis from radiation pneumonitis for patients with non-small cell lung cancer. Front Immunol 2022; 13: 870842.","journal-title":"Front Immunol"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2214\/AJR.21.25454","article-title":"Imaging of oncologic treatment-related pneumonitis: a focused review on emerging issues of immune checkpoint inhibitor pneumonitis, from the AJR special series on inflammation","volume":"218","author":"Nishino","year":"2022","unstructured":"Nishino M. Imaging of oncologic treatment-related pneumonitis: a focused review on emerging issues of immune checkpoint inhibitor pneumonitis, from the AJR special series on inflammation. AJR Am J Roentgenol 2022; 218: 19-27.","journal-title":"AJR Am J Roentgenol"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"1504826","DOI":"10.3389\/fmicb.2024.1504826","article-title":"Comparison of antifungal drugs in the treatment of invasive pulmonary aspergillosis: a systematic review and network meta-analysis","volume":"15","author":"Cheng","year":"2024","unstructured":"Cheng J, Han H, Kang W, Cai Z, Zhan P and Lv T. Comparison of antifungal drugs in the treatment of invasive pulmonary aspergillosis: a systematic review and network meta-analysis. Front Microbiol 2024; 15: 1504826.","journal-title":"Front Microbiol"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12941-021-00448-5","article-title":"Rapid and precise diagnosis of pneumonia coinfected by Pneumocystis jirovecii and Aspergillus fumigatus assisted by next-generation sequencing in a patient with systemic lupus erythematosus: a case report","volume":"20","author":"Chen","year":"2021","unstructured":"Chen Y, Ai L, Zhou Y, Zhao Y, Huang J, Tang W and Liang Y. Rapid and precise diagnosis of pneumonia coinfected by Pneumocystis jirovecii and Aspergillus fumigatus assisted by next-generation sequencing in a patient with systemic lupus erythematosus: a case report. Ann Clin Microbiol Antimicrob 2021; 20: 47.","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"Marmor HN, Kammer MN, Deppen SA, Shipe M, Welty VF, Patel K, Godfrey C, Billatos E, Herman JG, Wilson DO, Kussrow AK, Bornhop DJ, Maldonado F, Chen H and Grogan EL. Improving lung cancer diagnosis with cancer, fungal, and imaging biomarkers. J Thorac Cardiovasc Surg 2023; 166: 669-678, e4.","DOI":"10.1016\/j.jtcvs.2022.12.014"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/bs.acc.2024.06.002","article-title":"Sputum proteomics in lung disorders","volume":"122","author":"Iadarola","year":"2024","unstructured":"Iadarola P, D’Amato M, Grignano MA and Viglio S. Sputum proteomics in lung disorders. Adv Clin Chem 2024; 122: 171-208.","journal-title":"Adv Clin Chem"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"220114","DOI":"10.1183\/16000617.0114-2022","article-title":"Pulmonary aspergillosis: diagnosis and treatment","volume":"31","author":"Lamoth","year":"2022","unstructured":"Lamoth F and Calandra T. Pulmonary aspergillosis: diagnosis and treatment. Eur Respir Rev 2022; 31: 220114.","journal-title":"Eur Respir Rev"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12879-025-10627-w","article-title":"Efficacy and safety of isavuconazole versus voriconazole for the treatment of invasive fungal infections: a meta-analysis with trial sequential analysis","volume":"25","author":"Weng","year":"2025","unstructured":"Weng J, Du X, Fang B, Li Y, Huang L and Ju Y. Efficacy and safety of isavuconazole versus voriconazole for the treatment of invasive fungal infections: a meta-analysis with trial sequential analysis. BMC Infect Dis 2025; 25: 230.","journal-title":"BMC Infect Dis"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.3390\/biomedicines11123130","article-title":"Influence of rifamycin on survival in patients with concomitant lung cancer and pulmonary tuberculosis","volume":"11","author":"HS","year":"2023","unstructured":"Lee HS, Wei YF and Shu CC. Influence of rifamycin on survival in patients with concomitant lung cancer and pulmonary tuberculosis. Biomedicines 2023; 11: 3130.","journal-title":"Biomedicines"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"1561719","DOI":"10.3389\/fimmu.2025.1561719","article-title":"Where lung cancer and tuberculosis intersect: recent advances","volume":"16","author":"Fang","year":"2025","unstructured":"Fang C, He X, Tang F, Wang Z, Pan C, Zhang Q, Wu J, Wang Q, Liu D and Zhang Y. Where lung cancer and tuberculosis intersect: recent advances. Front Immunol 2025; 16: 1561719.","journal-title":"Front Immunol"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1016\/S0140-6736(22)01883-9","article-title":"9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2\/3 non-inferiority trial in South Korea","volume":"400","author":"Mok","year":"2022","unstructured":"Mok J, Lee M, Kim DK, Kim JS, Jhun BW, Jo KW, Jeon D, Lee T, Lee JY, Park JS, Lee SH, Kang YA, Lee JK, Kwak N, Ahn JH, Shim TS, Kim SY, Kim S, Kim K, Seok KH, Yoon S, Kim YR, Kim J, Yim D, Hahn S, Cho SN and Yim JJ; MDR-END investigators. 9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2\/3 non-inferiority trial in South Korea. Lancet 2022; 400: 1522-1530.","journal-title":"Lancet"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"115455","DOI":"10.1016\/j.intimp.2025.115455","article-title":"Host-directed immunotherapy to enhance treatment of Mycobacterium tuberculosis infection","volume":"165","author":"Fang","year":"2025","unstructured":"Fang R, Yang X, Li X, Xing J, Sun M, Zhang Y and Song N. Host-directed immunotherapy to enhance treatment of Mycobacterium tuberculosis infection. Int Immunopharmacol 2025; 165: 115455.","journal-title":"Int Immunopharmacol"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1177\/10915818251345116","article-title":"Predictive modeling of pharmacokinetic drug-drug and herb-drug interactions in oncology: insights from PBPK studies","volume":"44","author":"Ta&#x15F","year":"2025","unstructured":"Taş EE and Ulgen KO. Predictive modeling of pharmacokinetic drug-drug and herb-drug interactions in oncology: insights from PBPK studies. Int J Toxicol 2025; 44: 424-440.","journal-title":"Int J Toxicol"},{"key":"ref89","doi-asserted-by":"publisher","unstructured":"Li J, Fan J, Tan Z, Li A, He S, Jia Y, Li R, Lin Y, Liu Z, Chu H and Zhang Z. Clinical analysis of pulmonary nontuberculous mycobacterial infection in patients with pre-existing stage II-IV lung cancer. Clin Exp Pharmacol Physiol 2025; 52: e70060.","DOI":"10.1111\/1440-1681.70060"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.jiac.2023.07.008","article-title":"Immunogenicity and safety of influenza vaccine in patients with lung cancer receiving immune checkpoint inhibitors: a single-center prospective cohort study","volume":"29","author":"Nakashima","year":"2023","unstructured":"Nakashima K, Homma Y, Taniguchi J, Kubota N, Otsuki A, Ito H, Otsuka Y, Kondo K, Ohfuji S, Fukushima W and Hirota Y. Immunogenicity and safety of influenza vaccine in patients with lung cancer receiving immune checkpoint inhibitors: a single-center prospective cohort study. J Infect Chemother 2023; 29: 1038-1045.","journal-title":"J Infect Chemother"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ijid.2021.03.072","article-title":"Invasive pneumococcal disease among adults with hematological and solid organ malignancies: a population-based cohort study","volume":"106","author":"Garrido HM","year":"2021","unstructured":"Garcia Garrido HM, Knol MJ, Heijmans J, van Sorge NM, Sanders EAM, Klümpen HJ, Grobusch MP and Goorhuis A. Invasive pneumococcal disease among adults with hematological and solid organ malignancies: a population-based cohort study. Int J Infect Dis 2021; 106: 237-245.","journal-title":"Int J Infect Dis"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3390\/vaccines10020311","article-title":"Low adherence to pneumococcal vaccination in lung cancer patients in a tertiary care university hospital in Southern Germany","volume":"10","author":"Mohr","year":"2022","unstructured":"Mohr A, Kloos M, Schulz C, Pfeifer M, Salzberger B, Bauernfeind S, Hitzenbichler F, Plentz A, Loew T and Koch M. Low adherence to pneumococcal vaccination in lung cancer patients in a tertiary care university hospital in Southern Germany. Vaccines (Basel) 2022; 10: 311.","journal-title":"Vaccines (Basel)"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s11764-020-00927-2","article-title":"Factors associated with pneumococcal vaccination uptake by cancer survivors","volume":"15","author":"Song","year":"2021","unstructured":"Song YM, Shin J, Ko H, Yoo JE, Cho IY, Shin DW, Cho B, Lee JE, Hwang J and Lee J. Factors associated with pneumococcal vaccination uptake by cancer survivors. J Cancer Surviv 2021; 15: 234-243.","journal-title":"J Cancer Surviv"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update","volume":"36","author":"Taplitz","year":"2018","unstructured":"Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, Langston AA, Nastoupil LJ, Rajotte M, Rolston KV, Strasfeld L and Flowers CR. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol 2018; 36: 3043-3054.","journal-title":"J Clin Oncol"},{"key":"ref95","doi-asserted-by":"publisher","unstructured":"Bavaro DF, Pizzutilo P, Catino A, Signorile F, Pesola F, Di Gennaro F, Cassiano S, Marech I, Lamorgese V, Angarano G, Monno L, Saracino A and Galetta D. Incidence of infections and predictors of mortality during checkpoint inhibitor immunotherapy in patients with advanced lung cancer: a retrospective cohort study. Open Forum Infect Dis 2021; 8: ofab187.","DOI":"10.1093\/ofid\/ofab187"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"200076","DOI":"10.1183\/20734735.0076-2020","article-title":"Multidisciplinary care models for patients with lung cancer","volume":"16","author":"Hardavella","year":"2020","unstructured":"Hardavella G, Frille A, Theochari C, Keramida E, Bellou E, Fotineas A, Bracka I, Pappa L, Zagana V, Palamiotou M, Demertzis P and Karampinis I. Multidisciplinary care models for patients with lung cancer. Breathe (Sheff) 2020; 16: 200076.","journal-title":"Breathe (Sheff)"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.3855\/jidc.16495","article-title":"Healthcare-associated infections in patients who are immunosuppressed due to chemotherapy treatment: a narrative review","volume":"16","author":"Da Silva","year":"2022","unstructured":"Da Silva R and Casella T. Healthcare-associated infections in patients who are immunosuppressed due to chemotherapy treatment: a narrative review. J Infect Dev Ctries 2022; 16: 1784-1795.","journal-title":"J Infect Dev Ctries"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1002\/cpt.2015","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2C19 and proton pump inhibitor dosing","volume":"109","author":"Lima","year":"2021","unstructured":"Lima JJ, Thomas CD, Barbarino J, Desta Z, Van Driest SL, El Rouby N, Johnson JA, Cavallari LH, Shakhnovich V, Thacker DL, Scott SA, Schwab M, Uppugunduri CRS, Formea CM, Franciosi JP, Sangkuhl K, Gaedigk A, Klein TE, Gammal RS and Furuta T. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2C19 and proton pump inhibitor dosing. Clin Pharmacol Ther 2021; 109: 1417-1423.","journal-title":"Clin Pharmacol Ther"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","unstructured":"Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G and Zitvogel L. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 2018; 359: 91-97.","journal-title":"Science"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"5487","DOI":"10.1158\/1078-0432.CCR-20-1876","article-title":"Concomitant proton pump inhibitor use and survival in urothelial carcinoma treated with atezolizumab","volume":"26","author":"Hopkins","year":"2020","unstructured":"Hopkins AM, Kichenadasse G, Karapetis CS, Rowland A and Sorich MJ. Concomitant proton pump inhibitor use and survival in urothelial carcinoma treated with atezolizumab. Clin Cancer Res 2020; 26: 5487-5493.","journal-title":"Clin Cancer Res"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1126\/science.abb5920","article-title":"Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients","volume":"371","author":"Baruch","year":"2021","unstructured":"Baruch EN, Youngster I, Ben-Betzalel G, Ortenberg R, Lahat A, Katz L, Adler K, Dick-Necula D, Raskin S, Bloch N, Rotin D, Anafi L, Avivi C, Melnichenko J, Steinberg-Silman Y, Mamtani R, Harati H, Asher N, Shapira-Frommer R, Brosh-Nissimov T, Eshet Y, Ben-Simon S, Ziv O, Khan MAW, Amit M, Ajami NJ, Barshack I, Schachter J, Wargo JA, Koren O, Markel G and Boursi B. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science 2021; 371: 602-609.","journal-title":"Science"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer","volume":"36","author":"KC","year":"2018","unstructured":"Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, Martínez-Bernal G, Ferrara R, Lai WV, Hendriks LEL, Sabari JK, Caramella C, Plodkowski AJ, Halpenny D, Chaft JE, Planchard D, Riely GJ, Besse B and Hellmann MD. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol 2018; 36: 2872-2878.","journal-title":"J Clin Oncol"},{"key":"ref103","doi-asserted-by":"publisher","unstructured":"Gazzaniga FS and Kasper DL. The gut microbiome and cancer response to immune checkpoint inhibitors. J Clin Invest 2025; 135: e184321.","DOI":"10.1172\/JCI184321"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1038\/s41467-021-24331-1","article-title":"Microbial short-chain fatty acids modulate CD8(+) T cell responses and improve adoptive immunotherapy for cancer","volume":"12","author":"Luu","year":"2021","unstructured":"Luu M, Riester Z, Baldrich A, Reichardt N, Yuille S, Busetti A, Klein M, Wempe A, Leister H, Raifer H, Picard F, Muhammad K, Ohl K, Romero R, Fischer F, Bauer CA, Huber M, Gress TM, Lauth M, Danhof S, Bopp T, Nerreter T, Mulder IE, Steinhoff U, Hudecek M and Visekruna A. Microbial short-chain fatty acids modulate CD8(+) T cell responses and improve adoptive immunotherapy for cancer. Nat Commun 2021; 12: 4077.","journal-title":"Nat Commun"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"2249143","DOI":"10.1080\/19490976.2023.2249143","article-title":"Microbial metabolite butyrate promotes anti-PD-1 antitumor efficacy by modulating T cell receptor signaling of cytotoxic CD8 T cell","volume":"15","author":"Zhu","year":"2023","unstructured":"Zhu X, Li K, Liu G, Wu R, Zhang Y, Wang S, Xu M, Lu L and Li P. Microbial metabolite butyrate promotes anti-PD-1 antitumor efficacy by modulating T cell receptor signaling of cytotoxic CD8 T cell. Gut Microbes 2023; 15: 2249143.","journal-title":"Gut Microbes"},{"key":"ref106","doi-asserted-by":"publisher","unstructured":"Bachem A, Makhlouf C, Binger KJ, de Souza DP, Tull D, Hochheiser K, Whitney PG, Fernandez-Ruiz D, Dähling S, Kastenmüller W, Jönsson J, Gressier E, Lew AM, Perdomo C, Kupz A, Figgett W, Mackay F, Oleshansky M, Russ BE, Parish IA, Kallies A, McConville MJ, Turner SJ, Gebhardt T and Bedoui S. Microbiota-derived short-chain fatty acids promote the memory potential of antigen-activated CD8(+) T Cells. Immunity 2019; 51: 285-297, e5.","DOI":"10.1016\/j.immuni.2019.06.002"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"2307542","DOI":"10.1080\/19490976.2024.2307542","article-title":"Gut microbiota modulate CD8(+) T cell immunity in gastric cancer through Butyrate\/GPR109A\/HOPX","volume":"16","author":"Yu","year":"2024","unstructured":"Yu X, Ou J, Wang L, Li Z, Ren Y, Xie L, Chen Z, Liang J, Shen G, Zou Z, Zhao C, Li G and Hu Y. Gut microbiota modulate CD8(+) T cell immunity in gastric cancer through Butyrate\/GPR109A\/HOPX. Gut Microbes 2024; 16: 2307542.","journal-title":"Gut Microbes"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"100530","DOI":"10.1016\/j.medj.2024.10.007","article-title":"Effects of gut microbiota on immune checkpoint inhibitors in multi-cancer and as microbial biomarkers for predicting therapeutic response","volume":"6","author":"Lin","year":"2025","unstructured":"Lin Y, Xie M, Lau HC, Zeng R, Zhang R, Wang L, Li Q, Wang Y, Chen D, Jiang L, Damsky W and Yu J. Effects of gut microbiota on immune checkpoint inhibitors in multi-cancer and as microbial biomarkers for predicting therapeutic response. Med 2025; 6: 100530.","journal-title":"Med"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41698-024-00630-w","article-title":"Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapy","volume":"8","author":"Elkrief","year":"2024","unstructured":"Elkrief A, Méndez-Salazar EO, Maillou J, Vanderbilt CM, Gogia P, Desilets A, Messaoudene M, Kelly D, Ladanyi M, Hellmann MD, Zitvogel L, Rudin CM, Routy B, Derosa L and Schoenfeld AJ. Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapy. NPJ Precis Oncol 2024; 8: 143.","journal-title":"NPJ Precis Oncol"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"1075593","DOI":"10.3389\/fonc.2023.1075593","article-title":"A systematic review and meta-analysis evaluating the impact of antibiotic use on the clinical outcomes of cancer patients treated with immune checkpoint inhibitors","volume":"13","author":"Crespin","year":"2023","unstructured":"Crespin A, Le Bescop C, de Gunzburg J, Vitry F, Zalcman G, Cervesi J and Bandinelli PA. A systematic review and meta-analysis evaluating the impact of antibiotic use on the clinical outcomes of cancer patients treated with immune checkpoint inhibitors. Front Oncol 2023; 13: 1075593.","journal-title":"Front Oncol"},{"key":"ref111","doi-asserted-by":"publisher","unstructured":"Goldberg C, Nelson J, Rua M, Bannerji R, Setoguchi S and Bates B. Association between antibiotic use and mortality among older persons receiving first-line immune checkpoint inhibitors for non-small cell lung cancer (NSCLC). J Clin Oncol 2024; 42: e14607.","DOI":"10.1200\/JCO.2024.42.16_suppl.e14607"},{"key":"ref112","unstructured":"Qiu H, Ma QG, Chen XT, Wen X, Zhang N, Liu WM, Wang TT and Zhang LZ. Different classes of antibiotics exhibit disparate negative impacts on the therapeutic efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients. Am J Cancer Res 2022; 12: 3175-3184."},{"key":"ref113","doi-asserted-by":"publisher","first-page":"753234","DOI":"10.3389\/fonc.2022.753234","article-title":"An up-to-date investigation into the correlation between proton pump inhibitor use and the clinical efficacy of immune checkpoint inhibitors in advanced solid cancers: a systematic review and meta-analysis","volume":"12","author":"Liu","year":"2022","unstructured":"Liu C, Guo H, Mao H, Tong J, Yang M and Yan X. An up-to-date investigation into the correlation between proton pump inhibitor use and the clinical efficacy of immune checkpoint inhibitors in advanced solid cancers: a systematic review and meta-analysis. Front Oncol 2022; 12: 753234.","journal-title":"Front Oncol"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"1518474","DOI":"10.3389\/fonc.2025.1518474","article-title":"Gut microbes and immunotherapy for non-small cell lung cancer: a systematic review","volume":"15","author":"Jin","year":"2025","unstructured":"Jin Y, Jie Z and Fan X. Gut microbes and immunotherapy for non-small cell lung cancer: a systematic review. Front Oncol 2025; 15: 1518474.","journal-title":"Front Oncol"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00134-019-05866-w","article-title":"Antimicrobial de-escalation in critically ill patients: a position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Critically Ill Patients Study Group (ESGCIP)","volume":"46","author":"Tabah","year":"2020","unstructured":"Tabah A, Bassetti M, Kollef MH, Zahar JR, Paiva JA, Timsit JF, Roberts JA, Schouten J, Giamarellou H, Rello J, De Waele J, Shorr AF, Leone M, Poulakou G, Depuydt P and Garnacho-Montero J. Antimicrobial de-escalation in critically ill patients: a position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Critically Ill Patients Study Group (ESGCIP). Intensive Care Med 2020; 46: 245-265.","journal-title":"Intensive Care Med"},{"key":"ref116","doi-asserted-by":"publisher","first-page":"2374954","DOI":"10.1080\/2162402X.2024.2374954","article-title":"Faecalibaterium prausnitzii strain EXL01 boosts efficacy of immune checkpoint inhibitors","volume":"13","author":"Bredon","year":"2024","unstructured":"Bredon M, Danne C, Pham HP, Ruffié P, Bessede A, Rolhion N, Creusot L, Brot L, Alonso I, Langella P, Derosa L, Cortot AB, Routy B, Zitvogel L, Segata N and Sokol H. Faecalibaterium prausnitzii strain EXL01 boosts efficacy of immune checkpoint inhibitors. Oncoimmunology 2024; 13: 2374954.","journal-title":"Oncoimmunology"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper","volume":"46","author":"Abdul-Aziz MH","year":"2020","unstructured":"Abdul-Aziz MH, Alffenaar JC, Bassetti M, Bracht H, Dimopoulos G, Marriott D, Neely MN, Paiva JA, Pea F, Sjovall F, Timsit JF, Udy AA, Wicha SG, Zeitlinger M, De Waele JJ and Roberts JA; Infection Section of European Society of Intensive Care Medicine (ESICM); Pharmacokinetic\/pharmacodynamic and Critically Ill Patient Study Groups of European Society of Clinical Microbiology and Infectious Diseases (ESCMID); Infectious Diseases Group of International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT); Infections in the ICU and Sepsis Working Group of International Society of Antimicrobial Chemotherapy (ISAC). Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. Intensive Care Med 2020; 46: 1127-1153.","journal-title":"Intensive Care Med"}],"container-title":["American Journal of Cancer Research"],"original-title":[],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T05:52:37Z","timestamp":1768974757000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/12\/ajcr0169321.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":118,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/dagz2151","relation":{},"ISSN":["2156-6976"],"issn-type":[{"value":"2156-6976","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}